Evrysdi

News

England to start screening newborns for rare disease SMA

All newborns in England will be screened for rare muscle-wasting disease spinal muscular atrophy from 2027, in a landmark move for patients.

News

SMA treatment with Evrysdi 'could start prenatally'

Should treatment of neurodegenerative disorder SMA with Roche's Evrysdi start even before birth? One case study suggests so.

News

US/EU regulators start review of Biogen's high-dose Spinraza

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?

News

Roche Q3 results show steep fall-off in COVID product sales

Roche's third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the p

News

Roche puts pressure on SMA rivals with new FDA approval

Roche and PTC Therapeutics' Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger children with the rare disease, extending its use to include infants less than

News

Biogen looks beyond Spinraza in SMA with Ionis deal

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

England to start screening newborns for rare disease SMA

SMA treatment with Evrysdi 'could start prenatally'

US/EU regulators start review of Biogen's high-dose Spinraza

Roche Q3 results show steep fall-off in COVID product sales

Roche puts pressure on SMA rivals with new FDA approval

Biogen looks beyond Spinraza in SMA with Ionis deal

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Evrysdi

Editor's Picks